186 related articles for article (PubMed ID: 36860908)
1. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Quandt Z; Kim S; Villanueva-Meyer J; Coupe C; Young A; Kang JH; Yazdany J; Schmajuk G; Rush S; Ziv E; Perdigoto AL; Herold K; Lechner MG; Su MA; Tyrrell JB; Bluestone J; Anderson M; Masharani U
J Endocr Soc; 2023 Feb; 7(4):bvad012. PubMed ID: 36860908
[TBL] [Abstract][Full Text] [Related]
2. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
3. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.
Jessel S; Weiss SA; Austin M; Mahajan A; Etts K; Zhang L; Aizenbud L; Perdigoto AL; Hurwitz M; Sznol M; Herold KC; Kluger HM
Front Oncol; 2022; 12():836859. PubMed ID: 35350573
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
7. Two Cases of Atezolizumab-Induced Hypophysitis.
Kanie K; Iguchi G; Bando H; Fujita Y; Odake Y; Yoshida K; Matsumoto R; Fukuoka H; Ogawa W; Takahashi Y
J Endocr Soc; 2018 Jan; 2(1):91-95. PubMed ID: 29362727
[TBL] [Abstract][Full Text] [Related]
8. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
9. Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.
Menotti S; Giampietro A; Raia S; Veleno M; Angelini F; Tartaglione T; Gaudino S; Doglietto F; De Marinis L; Pontecorvi A; Bianchi A; Chiloiro S
J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623461
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
11. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
12. Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
Galligan A; Iravani A; Lasocki A; Wallace R; Weppler AM; Sachithanandan N; Chiang C; Colman PG; Wentworth J; Spain L; Au-Yeung G; Lee B; Kay TWH; Hicks RJ; Sandhu S; Krishnamurthy B
Front Endocrinol (Lausanne); 2023; 14():1295865. PubMed ID: 38093958
[TBL] [Abstract][Full Text] [Related]
13. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
[No Abstract] [Full Text] [Related]
14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
15. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
[TBL] [Abstract][Full Text] [Related]
16. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.
Fukuda I
J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122
[TBL] [Abstract][Full Text] [Related]
18. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
Kotwal A
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
[TBL] [Abstract][Full Text] [Related]
19. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
[TBL] [Abstract][Full Text] [Related]
20. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
